Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $58.97 USD
Change Today +5.67 / 10.64%
Volume 1.6M
CPHD On Other Exchanges
As of 8:10 PM 04/24/15 All times are local (Market data is delayed by at least 15 minutes).

cepheid inc (CPHD) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/24/15 - $62.00
52 Week Low
07/31/14 - $36.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CEPHEID INC (CPHD)

cepheid inc (CPHD) Related Businessweek News

No Related Businessweek News Found

cepheid inc (CPHD) Details

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company primarily offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual health, women’s health, virology, oncology, and genetics. It also provides SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample; and GeneXpert Infinity System for high volume testing. The company sells its products through its direct sales force and distributors worldwide. It has collaboration agreements with FIND to develop a test that can detect mycobactrium tuberculosis and associated rifampin resistance from human sputum samples; Life Technologies Corporation to develop reagents for use in the USPS BDS program; AstraZeneca plc, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, and others to develop Xpert Carba-R, a rapid diagnostic test; and Paul G. Allen Family Foundation and the BMGF to develop Xpert Ebola, a rapid test that. The company was incorporated in 1996 and is headquartered in Sunnyvale, California.

1,400 Employees
Last Reported Date: 02/26/15
Founded in 1996

cepheid inc (CPHD) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $664.9K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $398.0K
President of Hbdc
Total Annual Compensation: $433.5K
Chief Regulatory Officer and Executive Vice P...
Total Annual Compensation: $352.5K
Executive Vice President of Worldwide Commerc...
Total Annual Compensation: $236.2K
Compensation as of Fiscal Year 2014.

cepheid inc (CPHD) Key Developments

Cepheid Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Second and Third Quarter of 2015 and for the Year Ending December 31, 2015

Cepheid reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported revenue of $132.6 million, representing growth of 24% from $106.9 million for the first quarter of 2014. Net income was $0.9 million or $0.01 per basic and diluted share, which compares to net loss of $9.3 million or $0.13 per share, in the first quarter of 2014. Non-GAAP net income was $12.4 million, or $0.17 per diluted share compared to a non-GAAP net loss of $0.6 million, or $0.01 per diluted share, in the first quarter of 2014. Income from operations was $4.605 million against loss of $6.332 million a year ago. Income before income taxes was $0.430 million against loss of $8.623 million a year ago. Net cash provided by operating activities was $0.738 million against net cash used in operating activities of $16.856 million a year ago. Capital expenditures were $9.989 million against $8.762 million a year ago. Non-GAAP income from operations was $13.570 million against $1.102 million a year ago. For the fiscal year ending December 31, 2015, the company now expects total revenue to be in the range of $542 to $553 million, net loss in the range of $0.47 to $0.43 per share and non-GAAP net income in the range of $0.25 to $0.29 per share. The company expects non-GAAP gross margin of approximately 53% for the full year. The company expects second quarter of 2015 revenue to be in the $128 million to $131 million range. The company expects second quarter gross margin of approximately 51%, down from the strong first quarter, but up slightly from the second quarter of 2014 when the company shipped a sizable HBDC order to China. The company expects non-GAAP net loss of $0.05 to $0.06 per share. The company expects to return to non-GAAP profitability in the third quarter of 2015.

Cepheid Appoints Ilan Daskal as Executive Vice President and Chief Financial Officer

Cepheid reported that it has appointed Ilan Daskal to the position of Executive Vice President and Chief Financial Officer. Daskal assumes responsibility for worldwide finance operations, information technology, and investor relations. Daskal brings more than 20 years of finance experience to Cepheid, most recently as Executive Vice President and Chief Financial Officer at International Rectifier Corp., from 2008 through its acquisition in January 2015 by Infineon Technologies AG. Prior to joining International Rectifier, Daskal most recently served as Vice President Finance and Business Administration, Communication Division North America for Infineon Technologies AG from 2001 through 2008, in addition to earlier positions as Chief Financial Officer at both Savan Communication Ltd. and SmartLink Ltd.

Cepheid and FIND Announce European Approval of Xpert HIV-1 Qual

Cepheid and FIND announced that Xpert HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on the Cepheid GeneXpert System. The World Health Organization estimates that 35 million people worldwide are currently living with HIV/AIDS. 1 Of those infected, 2.3 million represent new infections and an estimated 260,000 are children. Without timely HIV testing and therapy initiation, one third of HIV-infected infants will die before their first birthday and more than 50% will die before reaching two years of age.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPHD:US $58.97 USD +5.67

CPHD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DiaSorin SpA €41.09 EUR +0.17
Luminex Corp $16.10 USD -0.18
Meridian Bioscience Inc $19.13 USD +0.33
QIAGEN NV €22.90 EUR +0.004
Seegene Inc 36,500 KRW -1,200.00
View Industry Companies

Industry Analysis


Industry Average

Valuation CPHD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.5x
Price/Book 11.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 7.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CEPHEID INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at